Kinnate Biopharma Inc (KNTE)

$2.49

-0.01

(-0.4%)

Market is closed - opens 8 PM, 29 Feb 2024

Insights on Kinnate Biopharma Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 73.4% return, outperforming this stock by 126.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 243.1% return, outperforming this stock by 335.6%

Performance

  • $2.46
    $2.51
    $2.49
    downward going graph

    1.2%

    Downside

    Day's Volatility :1.8%

    Upside

    0.6%

    downward going graph
  • $1.04
    $7.19
    $2.49
    downward going graph

    58.23%

    Downside

    52 Weeks Volatility :85.54%

    Upside

    65.37%

    downward going graph

Returns

PeriodKinnate Biopharma IncSector (Health Care)Index (Russel 2000)
3 Months
15.21%
13.2%
0.0%
6 Months
16.28%
9.7%
0.0%
1 Year
-52.65%
15.4%
-6.7%
3 Years
-92.71%
30.3%
-19.6%

Highlights

Market Capitalization
117.7M
Book Value
$3.66
Earnings Per Share (EPS)
-2.78
Wall Street Target Price
2.36
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-33.63%
Return On Equity TTM
-55.8%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-131.8M
Diluted Eps TTM
-2.78
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.5
EPS Estimate Next Year
-1.27
EPS Estimate Current Quarter
-0.67
EPS Estimate Next Quarter
-0.41

Analyst Recommendation

Buy
    61%Buy
    38%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Kinnate Biopharma Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
12
Hold
5
5
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Downside of 5.22%

Current $2.49
Target $2.36

Technicals Summary

Sell

Neutral

Buy

Kinnate Biopharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kinnate Biopharma Inc
Kinnate Biopharma Inc
3.31%
16.28%
-52.65%
-92.71%
-93.59%
Moderna, Inc.
Moderna, Inc.
-8.24%
-15.49%
-30.7%
-38.88%
325.66%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.93%
19.55%
30.63%
114.52%
130.61%
Novo Nordisk A/s
Novo Nordisk A/s
12.12%
30.39%
73.39%
235.66%
399.41%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.12%
22.56%
48.44%
104.83%
128.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kinnate Biopharma Inc
Kinnate Biopharma Inc
NA
NA
NA
-2.5
-0.56
-0.34
NA
3.66
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.94
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.21
28.21
2.0
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.17
45.17
4.45
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.25
31.25
0.59
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kinnate Biopharma Inc
Kinnate Biopharma Inc
Buy
$117.7M
-93.59%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$35.9B
325.66%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$107.8B
130.61%
28.21
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$544.3B
399.41%
45.17
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$112.0B
128.3%
31.25
36.68%

Institutional Holdings

  • Foresite Capital Management IV, LLC

    20.53%
  • Orbimed Advisors, LLC

    17.00%
  • Foresite Capital Management V, LLC

    7.48%
  • Nextech Invest AG

    4.94%
  • Vida Ventures Advisors, LLC

    4.69%
  • Viking Global Investors LP

    3.86%

Corporate Announcements

  • Kinnate Biopharma Inc Earnings

    Kinnate Biopharma Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

kinnate biopharma inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. the company's lead product candidate is kin002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. its other products in preclinical stage include kin003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (fgfr)2 and fgfr3 genes; and small molecule research programs, including a cyclin-dependent kinase 12 inhibitor in its kin004 program. kinnate biopharma inc. was founded in 2018 and is headquartered in san diego, california.

Organization
Kinnate Biopharma Inc
Employees
84
CEO
Mr. Nima Farzan M.B.A.
Industry
Healthcare

FAQs